Browsing Tag
Horizon Therapeutics
7 posts
Why AnaptysBio’s new CFO hire may matter more than a routine biotech appointment
AnaptysBio is no longer a classic biotech pipeline bet. Christopher Murphy’s CFO appointment tests whether ANAB can execute as a royalty vehicle.
Amgen (AMGN) stock in focus as subcutaneous TEPEZZA Phase 3 data strengthens thyroid eye disease franchise
Amgen’s Phase 3 subcutaneous TEPEZZA win could reshape thyroid eye disease treatment and competition. Read what it means for AMGN now.
Amgen reports strong Q4 growth amid expanding product sales and biotech innovations
Amgen’s revenue growth for the fourth quarter of 2024 exceeded analyst expectations, reflecting the company’s expanding biopharmaceutical portfolio…
Horizon Therapeutics’ Daxdilimab Phase 2 trial fails to reach primary endpoint in SLE
Horizon Therapeutics plc (Nasdaq: HZNP) announced that its Phase 2 clinical trial studying the efficacy of daxdilimab in…
Amgen to acquire Irish biopharma company Horizon Therapeutics for $28bn
Amgen through its wholly-owned subsidiary Pillartree has agreed to acquire Ireland-based biopharmaceutical firm Horizon Therapeutics for an enterprise…
Glenmark Pharmaceuticals gets FDA final approval for Buphenyl generic
Glenmark Pharmaceuticals said that it has bagged final approval for Sodium Phenylbutyrate Tablets USP, 500 mg by the…
Horizon Therapeutics announces $3.05bn acquisition of Viela Bio to expand rare disease pipeline
In a major move to strengthen its leadership in rare diseases, Horizon Therapeutics, an Irish biopharmaceutical company, has…